Merus NV

Genmab achieved 21% revenue growth to $2.66 billion in the first nine months of 2025, driven primarily by increased DARZALEX and Kesimpta royalties.

Abivax shares soared over 850% following positive Phase III data in ulcerative colitis, creating an "Abivax effect" that has reshaped market dynamics and reignited investor confidence in European biotech.

Zenocutuzumab demonstrated a 37% objective response rate in 19 patients with NRG1-positive cholangiocarcinoma in the phase II eNRGy trial, with a median duration of response of 7.4 months.

Merus announced that interim data from its phase 2 trial of petosemtamab in metastatic colorectal cancer has been selected for a prestigious plenary session oral presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.

The biopharmaceutical sector experienced a significant surge in high-value acquisitions during Q3 2025, with four of the year's five largest deals occurring in the past four months.

Genmab will acquire Merus for $97.00 per share, representing a 41% premium and totaling approximately $5.2 billion in the largest deal in Genmab's history.

Biohaven's Trop2-directed ADC BHV-1510 demonstrated tumor reduction in all six patients when combined with cemiplimab, including confirmed partial responses and activity in brain metastases.

Merus announced that 79% of patients with newly diagnosed metastatic head and neck cancer survived at least one year when treated with petosemtamab in combination with Keytruda.

Merus will present updated interim Phase 2 data on petosemtamab combined with pembrolizumab for first-line treatment of PD-L1+ recurrent/metastatic head and neck squamous cell carcinoma at the 2025 ASCO Annual Meeting.

Merus N.V.'s petosemtamab receives FDA Breakthrough Therapy designation for first-line treatment of PD-L1 positive head and neck cancer when combined with pembrolizumab.